Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Diversify Advisory Services LLC

Diversify Advisory Services LLC boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 572.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,275 shares of the company's stock after purchasing an additional 101,529 shares during the quarter. Diversify Advisory Services LLC's holdings in Amneal Pharmaceuticals were worth $2,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMRX. Public Employees Retirement System of Ohio purchased a new position in Amneal Pharmaceuticals in the second quarter worth $29,000. Fortitude Family Office LLC grew its stake in Amneal Pharmaceuticals by 100.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,607 shares of the company's stock worth $32,000 after buying an additional 807 shares during the last quarter. GAMMA Investing LLC raised its stake in Amneal Pharmaceuticals by 54.9% in the third quarter. GAMMA Investing LLC now owns 1,605 shares of the company's stock valued at $32,000 after buying an additional 569 shares during the last quarter. KBC Group NV purchased a new stake in Amneal Pharmaceuticals in the first quarter valued at about $80,000. Finally, GK Wealth Management LLC acquired a new stake in Amneal Pharmaceuticals in the third quarter worth about $103,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Trading Down 0.5%

Shares of AMRX stock opened at $20.38 on Friday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $9.99 and a fifty-two week high of $21.17. The firm has a market capitalization of $6.51 billion, a P/E ratio of 41.59, a PEG ratio of 2.40 and a beta of 1.22. The stock's fifty day moving average is $18.79 and its two-hundred day moving average is $16.45. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.06. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares of the company's stock, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director John Kiely sold 50,000 shares of the firm's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the transaction, the director owned 210,252 shares of the company's stock, valued at $3,708,845.28. This trade represents a 19.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 over the last quarter. 17.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on AMRX. Leerink Partners initiated coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 9th. They set an "outperform" rating and a $23.00 price objective on the stock. Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an "outperform" rating and a $27.00 target price for the company. Weiss Ratings raised shares of Amneal Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. UBS Group reissued a "buy" rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Finally, Zacks Research lowered shares of Amneal Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, October 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $21.25.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company's generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.